Breast cancer affects more than 200,000 people every year in the U.S. There are many factors that may contribute to breast cancer risk, including genetic factors passed from generation to generation, as well as length of exposure to estrogen. This can include estrogen made within the own body during a person’s fertile years, or estrogen-like products in the environment. “As patients and physicians, we want to know exactly what caused the cancer,” says Kim, “but the truth is, it’s multifactorial. We can’t point to one thing and say: ‘Don’t eat red meat,’ or ‘Don’t drink diet Pepsi.’”
Because breast cancer is so varied, it can make screening recommendations difficult and ever changing. Kim tells her patients to go with their intuition. “If you notice something, get it checked out. We are in tune with our bodies, we know best. Sometimes that means we have to advocate for ourselves and insist on screening even if we fall below the recommended age frame,” she adds.
What Kim really appreciates about working at Fred Hutch is that she has access to many forms of radiation to formulate the best possible treatment plan for each individual. “It allows me to look at each person’s exact expression of the breast cancer, as well as their anatomy, to make a determination on treatment,” says Kim. “Proton therapy has the potential to mitigate long lasting side effects. Only a small amount of radiation to the heart can have detrimental effects on the organ, and that can’t be changed after the fact. If I can spare as much radiation as possible to healthy tissue using protons, then that’s what I will do. If photons can be used more effectively, I will use photons.”
Kim is seeing more breast cancer recurrences, not because the original treatment failed, but because patients are living longer. When she sees patients in their 60s and 70s who were treated in their 40s and early 50s, proton therapy allows her to treat the cancer despite the patients’ previous radiation treatment.
“The proton team is exceptional,” says Kim. “I had one case where the dosimetrist came up with a good plan for reirradiation. However, I needed her to improve it in certain areas. When she gave it back to me, she had exceeded all my expectations. I think that the team is a huge factor in the success of treatment."
"The number one thing I want patients to know is that they need to be comfortable with their team. They should feel good about asking questions, feel supported in their decision making. Medicine is an art as well as a science.”
Kim also encourages patients to join clinical trials. Fred Hutch offers many clinical trials to further our understanding of risk, treatment, screening effectiveness and more, including the RADCOMP trial, which is accepting new participants through the end of the year. Because it is such a large and long-lasting trial, it will give a lot of information about the effectiveness of proton therapy for breast cancer. RADCOMP will follow patients for 10 years or more and will look at long-term outcomes from surveys from both the patient and physician perspectives.
“I tell patients that clinical trials are so important to cancer care. By joining, they help future patients get the best possible treatments. It won’t negatively impact their own care, so I encourage them to ask if they are interested,” says Kim.
Where Kim feels the most need for improvement in health care is in access to medicine by marginalized groups. “I absolutely think there is disparity in care for ethnic minorities, LGPTQ+ populations, but also for people with mental illness. I think Fred Hutch is doing a great job with our commitment to diversity, inclusion and equity, but by the time they get to us, it’s often late in the game. A push to get all patients into care quickly regardless of insurance status, age, race, etc., to increase their chance of a successful outcome should be a priority at every clinic, from family care to cancer care.”